NCT04316494 - Hydroxychloroquine in ANCA Vasculitis Evaluation | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

December 17, 2020

Primary Completion Date

May 31, 2025

Study Completion Date

May 31, 2025

Conditions

ANCA Associated VasculitisMicroscopic PolyangiitisChurg-Strauss SyndromeWegener Granulomatosis

Interventions

DRUG

Hydroxychloroquine

"White, round, film-coated tablets marked 'HCQ' on one side and 200' on the other side.~Excipients:~Lactose monohydrate Maize Starch Magnesium Stearate Polyvidone Opadry OY-L-28900"

DRUG

Placebo

"Placebo to match Hydroxychloroquine.~Excipients:~Microcrystalline cellulose Lactose Magnesium Stearate"

Trial Locations (18)

RG1 5AN

Royal Berkshire NHS Foundation Trust, Reading

CB2 0QQ

Cambridge University Hospitals NHS Foundation Trust, Cambridge

SG1 4AB

East and North Hertfordshire NHS Trust, Stevenage

IV2 3JH

NHS Highland, Inverness

LE3 9QP

University Hospitals of Leicester NHS Trust, Leicester

L9 7AL

Liverpool University Hospitals NHS Foundation Trust, Liverpool

BA1 3NG

Royal United Hospitals Bath NHS Foundation Trust, Bath

RH1 5RH

Surrey and Sussex Healthcare NHS Trust, Redhill

BN2 5BE

University Hospitals Sussex NHS Foundation Trust, Brighton

CF14 4XW

Cardiff & Vale University Health Board, Cardiff

Unknown

Epsom and St Helier University Hospitals NHS Trust, Epsom

Cwm Taf Morgannwg University Health Board, Llantrisant

Oxford University Hospitals NHS Foundation Trust, Oxford

South Tyneside and Sunderland NHS Foundation Trust, Sunderland

Torbay and South Devon NHS Foundation Trust, Torquay

SE1 9RT

Guy's and St Thomas' NHS Foundation Trust, London

SE5 9RS

King's College Hospital NHS Foundation Trust, London

W12 0HS

Imperial College Healthcare NHS Trust, London